Photocure ASA (0IMT) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Photocure Asa.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.263 -- 00:00:04.629 All right. Well, good afternoon. Good morning to everyone. 00:00:04.629 -- 00:00:09.196 This is PhotoCare ASA fourth quarter and full year 2025 results. 00:00:09.196 -- 00:00:14.345 I'm Dan Schneider, President and CEO. Today with me is Eric Dahl, CFO, and Priyam 00:00:14.345 -- 00:00:17.911 Shah, our Vice President of IR. 00:00:17.911 -- 00:00:23.077 Just a reminder, the usual disclaimers are in effect for today's presentation. 00:00:23.504 -- 00:00:26.972 So I'd like to start off with the strategic priorities and initiatives of PhotoCare. 00:00:26.972 -- 00:00:32.744 Our strategic priorities guide how we execute and allocate resources across a company. 00:00:32.744 -- 00:00:36.599 At a high level, our strategy is centered around three key pillars. 00:00:36.599 -- 00:00:39.923 Strengthen the core Hexafix-SysFu business. 00:00:39.923 -- 00:00:45.449 Advance blue light cystoscopy as a definitive standard of care in bladder cancer. 00:00:45.449 -- 00:00:51.235 And third, expand our reach into a broader uro-oncology and precision diagnostic space. 00:00:51.235 -- 00:00:55.559 Taking a deeper dive in the first pillar, accelerate and expand, we need to deliver on 00:00:55.559 -- 00:01:00.985 our financial guidance for disciplined growth in revenue and EBITDA in our core business 00:01:00.985 -- 00:01:03.903 and continue generating operating leverage. 00:01:03.903 -- 00:01:08.945 We also need to drive the BLC mobile strategy for tech in the U.S., that 00:01:08.945 -- 00:01:13.610 hits the hospital markets or the hospitals who otherwise wouldn't have access to blue 00:01:13.610 -- 00:01:19.517 light cystoscopy. And in the EU, it's important we increase our penetration in our high-priority 00:01:19.517 -- 00:01:24.703 growth markets throug...